A number of imaging methods, such as C-11/F-18-choline, F-18-FACBC, and Ga-68-PSMA for positron emission tomography (PET) combined with CT (PET/CT) or magnetic resonance imaging (MRI), are currently under investigation to determine their utility for response assessment in prostate cancer and cannot yet be recommended for use in routine clinical practice. The gene discussed is FOLH1; the disease is Familial prostate cancer.